• Explore /
  • Poster
  • / Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

Abstract Poster

Authors

null

Luciana Vinti

IRCCS Ospedale Pediatrico Bambino Gesu, Rome, Italy

Luciana Vinti , Stephen Daw , Constantino Sabado Alvarez , Franca Fagioli , Auke Beishuizen , Gérard Michel , Maria Luisa Moleti , Michaela Cepelova , Anne Thorwarth , Charlotte Rigaud , Diego Plaza Lopez de Sabando , Judith Landman-Parker , Juan Shen , Pallavi Pillai , Patricia Marinello , Christine Mauz-Körholz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Leukemia/Lymphoma

Clinical Trial Registration Number

NCT03407144

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 10027)

DOI

10.1200/JCO.2023.41.16_suppl.10027

Abstract #

10027

Poster Bd #

333

Abstract Disclosures

Similar Posters

First Author: Christine Mauz-Körholz

First Author: Christine Mauz-Korholz

First Author: Jane N. Winter

Poster

2023 ASCO Annual Meeting

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

First Author: Carrie Ho